What’s Coming from Dexcom in 2020? A Low-Cost, Slimmer, Fully Disposable CGM, reported by Brian Levine and Adam Brown for diaTribe.org, 8 January 2019 … and this is exciting!
Dexcom and Verily are launching the G7, a much thinner, less expensive, fully disposable continuous glucose monitor, in the US in about late 2020, as the current estimate for the launch, followed by broader availability in 2021. In a presentation, Dexcom shared a new picture of the device previously coined the “thinnest CGM ever” that it is developing in partnership with Verily (the part of Alphabet formerly known as Google Life Sciences).
A couple years ago, it was described as having less volume than an M&M and being roughly the size of a penny, though this may have changed as the design has evolved. The device will have a number of additional features too:
- Significantly lower cost,
- Fully disposable – after a sensor wear, the entire piece of plastic will be throw out and a new one will be placed on,
- No fingersticks necessary,
- “Extended wear” – 14- to 15-day wear,
- Sends data straight to smartphones via Bluetooth.
Investors angry about insulin woes sue Novo Nordisk in Denmark for $1.75B was reported by Eric Sagonowsky for FiercePharma.com, 16 August 2019. Novo is being sued, in Denmark, by a group of investors, claiming it made “misleading” statements about its insulin sales. And the investors want payback—in a big way. They’re demanding about $1.75 billion in compensation.
Insulin makers have faced years of allegations, criticism and investigations over their prices, even as sales have fallen. In the U.S., list prices have climbed in recent years, as have rebates to pharma middlemen. That dynamic has led patients to pay more for their medicines, while drugmakers have reported flat or declining net sales.
Amid its insulin pricing squeeze, Novo has pivoted toward its GLP-1 franchise, hoping to rely less on the insulins for growth.
Medtronic on go to launch study of extended-use insulin infusion set was published by Douglas W. House for SeekingAlpha.com, 16 August 2019.
The goal of the study will be to collect clinical data to support the use of the extended wear infusion set for up to seven days – more than twice the length of time that any infusion set can currently be used. The multi-center, non-randomized, prospective single arm study will enroll up to 150 subjects, aged 18 to 80, with type 1 diabetes on insulin pump therapy.
Rating the Performance of Popular Diabetes Non-Profits was written by Sara Seitz for InsulinNation.com, 14 August 2019. While we are always looking for a better way to manage our diabetes, how can we help with our donation dollars? Some diabetes donation dollars go further than other!
Using the database of Charity Navigator — https://www.charitynavigator.org/—, a philanthropy watchdog organization, here’s a compiled statistics and grades on six popular diabetes research organizations. A couple of caveats:
- The scores are based on an analysis by Charity Navigator of each organization’s most recent fiscal year.
- While Charity Navigator is well-respected in the non-profit world, it is just one of several philanthropy watchdogs. Its assessment of a charity may differ from that of others.
- Some of the organizations below have regional arms that have their own Charity Navigator profile. In such cases, scores in this article only reflect the parent organization.
- Taking Control of Your Diabetes: 4 out of 4 stars – Overall Charity Navigator Score – 91.45
- Joslin Diabetes Center: 3 out of 4 stars – Overall Charity Navigator Score – 84.29
- Diabetes Research Institute Foundation: 3 out of 4 stars — Overall Charity Navigator Score– 84.16
- JDRF (formerly Juvenile Diabetes Research Foundation): 3 out of 4 stars — Overall Charity Navigator Score – 82.74
- Children’s Dia
- American Diabetes Association: 2 out of 4 — Overall Charity Navigator score – 73.21
And for fun, to see if you read all the way through this blog, here’s a story of a robotic “tail”! Indeed, Japanese Researchers Build Robotic Tail, as reported by Guardian News, 15 August 2019. A team of researchers at Japan’s Keio university have built a robotic tail. Dubbed ‘Arque’, the grey one-metre device mimics tails such as those of cheetahs and monkeys, used to keep balance while running and climbing. Researchers say it could help unsteady elderly people keep their balance … or perhaps help T1s who develop neuropathies and balance issues.